caa a22 4500 469026693 CHVBK 20180323132732.0 cr unu---uuuuu 170328e19920401xx s 000 0 eng 10.1007/BF01980479 doi (NATIONALLICENCE)springer-10.1007/BF01980479 Acitretin (Neotigason®) [Elektronische Daten] A review of pharmacokinetics and teratogenicity and hypothesis on metabolic pathways [M. Bouvy, M. Sturkenboom, M. Cornel, L. De Jong-Van den Berg, B. Stricker, H. Wesseling] Acitretin was introduced as a replacement for etretinate, the ethyl ester of acitretin. Acitretin is eliminated at a much faster rate than etretinate. Although both drugs are teratogens, the replacement was important especially as it allowed for a much shorter post-medication period in which pregnancy should be precluded. Recent findings showed the presence of etretinate in the plasma of acitretin-treated patients. This article gives a review of known metabolic pathways of the retinoids and tries to elucidate the possible conversion of acitretin into etretinate after acitretin ingestion. Royal Dutch Association for Advancement of Pharmacy, 1992 Acitretin nationallicence Etretinate nationallicence Metabolism nationallicence Pharmacokinetics nationallicence Retinoids nationallicence Teratogens nationallicence Bouvy M. Department of Pharmacology and Pharmacotherapeutics, Section Social Pharmacy, University Centre for Pharmacy, Ant. Deusinglaan 2, 9713, AW Groningen, the Netherlands aut Sturkenboom M. Department of Pharmacology and Pharmacotherapeutics, Section Social Pharmacy, University Centre for Pharmacy, Ant. Deusinglaan 2, 9713, AW Groningen, the Netherlands aut Cornel M. EUROCAT - Registration of congenital anomalies, Department of Medical Genetics, University of Groningen, Ant. Deusinglaan 2, 9713, AW Groningen, the Netherlands aut De Jong-Van den Berg L. Department of Pharmacology and Pharmacotherapeutics, Section Social Pharmacy, University Centre for Pharmacy, Ant. Deusinglaan 2, 9713, AW Groningen, the Netherlands aut Stricker B. Netherlands Centre for Monitoring of Adverse Reactions to Drugs, P.O. Box 5811, 2280, HK Rijswijk, the Netherlands aut Wesseling H. Department of Clinical Pharmacology, University of Groningen, the Netherlands aut Pharmaceutisch Weekblad Kluwer Academic Publishers 14/2(1992-04-01), 33-37 0031-6911 14:2<33 1992 14 11096 https://doi.org/10.1007/BF01980479 text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF01980479 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Bouvy M. Department of Pharmacology and Pharmacotherapeutics, Section Social Pharmacy, University Centre for Pharmacy, Ant. Deusinglaan 2, 9713, AW Groningen, the Netherlands aut NATIONALLICENCE 700 1- Sturkenboom M. Department of Pharmacology and Pharmacotherapeutics, Section Social Pharmacy, University Centre for Pharmacy, Ant. Deusinglaan 2, 9713, AW Groningen, the Netherlands aut NATIONALLICENCE 700 1- Cornel M. EUROCAT - Registration of congenital anomalies, Department of Medical Genetics, University of Groningen, Ant. Deusinglaan 2, 9713, AW Groningen, the Netherlands aut NATIONALLICENCE 700 1- De Jong-Van den Berg L. Department of Pharmacology and Pharmacotherapeutics, Section Social Pharmacy, University Centre for Pharmacy, Ant. Deusinglaan 2, 9713, AW Groningen, the Netherlands aut NATIONALLICENCE 700 1- Stricker B. Netherlands Centre for Monitoring of Adverse Reactions to Drugs, P.O. Box 5811, 2280, HK Rijswijk, the Netherlands aut NATIONALLICENCE 700 1- Wesseling H. Department of Clinical Pharmacology, University of Groningen, the Netherlands aut NATIONALLICENCE 773 0- Pharmaceutisch Weekblad Kluwer Academic Publishers 14/2(1992-04-01), 33-37 0031-6911 14:2<33 1992 14 11096 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer